Summary of Acute Lymphoblastic Leukemia Trials

(Back to the Leukemia page)

The links in the table below take you to informal pages on this site which list summaries of and comments on the current clinical trials for ALL. Many parents combined resources to gather this information, many thanks to all of them! If you have information or comments to add, feel free to email the editor as linked at the bottom of each page.

The links to the clinical trials on the site sometimes change as the site re-organizes. As of 4/06, you go to the main (advanced) search page on and select the type of cancer, then select whether the trial is open or closed and the Protocol ID. You can also search for all available trials by entering in other applicable information and leaving the Protocol ID field empty.

Relapse Protocols: On another page/site

 trial dates risk aim of trial is to compare:
CCG 1901 around 1994 high New York I and II
 CCG 1922 early 1990s


favorable to intermediate IV vs oral 6-MP

dexamethasone vs prednisone

CCG 1952 1996-2000


standard risk TG vs MP

TIT vs methotrexate IT

CCG 1961  1996-2000


 high risk  one vs two delints

standard vs intensified chemo

CCG 1991 2001 (closed to accrual) standard risk Escalating dose IV MT (w/o leucovorin rescue) vs oral MT

single vs double delints

POG 9904 2001 (closed to accrual) low-risk Compare short methotrexate infusion vs longer infusion.

Compare the above regimens of methotrexate, with or without intensification.

Less-intensive treatment for trisomy 4, 10; checking if can do the same for tel/aml t(12;21)

POG 9905 2001 (closed to accrual) standard risk Determine if delayed intensification improves outcome.

Compare short methotrexate infusion (4 hours) vs longer infusion (24 hours).

Determine the correlation between EFS, MRD, and RER in standard risk patients.

POG 9906 2001 (closed to accrual) high risk Determine whether augmented BFM therapy is superior to ALinc 14/15 therapy.
St Judes total therapy XV
(email the editor if interested in details)
2000 all risk groups St Judes site
AALL00P2 2001-2007 (completed)

phase II

T-cell Modified BFM with or without Nelarabine (Ara G pro-drug) in T-cell patients.
DFCI 00-01 (current in 2003) T-cell
POG 9404 (closed to accrual but still used) The main purpose of this study is to determine whether adding high dose methotrexate to other chemotherapy drugs is more effective in treating T-ALL and T-NHL.
POG 9406 closed high risk standard vs high dose methotrexate

standard araC/teniposide vs high dose ara C/asparaginase rescue

 POG 9605 closed

(about 95-98)

moderate risk to determine if delayed intensification with divided dose oral MTX improves efs

compare effect of twice vs once daily MP


activated about 4/2005

closed late 2010

standard risk (further classified as low-, average-, and high-risk)

ages 0-9, WBC less than 50K at dx, pre-B

  • increased asparaginase in the low-risk group
  • augmented interim maintenance and delayed intensification or intensified consolidation in the average-risk group
  • non-randomized augmented/intensified treatment with 2 DI's for the high-risk group
COG-AALL0232 closed early 2011
high risk

pre-B and age greater than 9 or WBC greater than 50K at dx

dexamethasone vs prednisone during induction

escalating dose methotrexate vs high dose methotrexate with leucovorin rescue during interim maintenance

COG-AALL0631 summary

activated 2008 infant ALL Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib)
COG-AALL0434 outline

activated 2007 T-cell ALL intensified mtx, Nelarabine, augmented BFM

COG-AALL0932 outline

activated 2010 NCI standard risk ALL and average risk ALL as determined by therapy response and/or genetics studies different maintenance therapy strategies for average risk patients (different 6MP doses and vincristine/dexamethasone pulses at 4 vs 12 week periods); standard risk patients have follow one of two different consolidation strategies; Downs syndrome patients have a separate arm

COG-AALL1131 outline

activated 4/2012 high-risk ALL Phase III Randomized Study of Consolidation Therapy, Interim Maintenance Therapy, Delayed Maintenance Therapy, and Maintenance Therapy in Children, Adolescents, and Young Adults With Newly Diagnosed High-Risk B-precursor Acute Lymphoblastic Leukemia

COG-AALL1122 outline

activated 2011 phase II trial for Ph+ ALL Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia - Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL).

COG-AALL0622 outline

activated 2011, closed to accrual 2012 NCI phase III trial for Ph+ ALL intensified Dasatinib therapy
 POG 9201

 POG 9005

92-96?  low risk ?
 CCG 1901  (early 90s)  high risk  
 RCCHOS    high risk  NOTE: this trial is used in S. Africa
Toronto Protocol C high risk

Would you like to add information? Email Patty.

Ped-Onc Resource Center Home

General Disclaimer : These pages are intended for informational purposes only and are not intended to render medical advice. The information provided on Ped Onc Resource Center should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you suspect your child has a health problem, you should consult your health care provider.

Last Updated 2/08

© copyright 1998-2018 by Patty Feist

email the editor